MAPT and tauopathy: There is a need for Tau imaging agents that can more reliably be useful below Braak IV stages of AD [21], discriminate between 3R and 4R Tau isoforms, have reduced off-target binding (such as binding to meninges [22]), and be useful for imaging other tauopathies [23].